Crispr Therapeutics AG (CRSP)
NASDAQ · Healthcare
Crispr Therapeutics AG Total Liabilities 2015–2025
Crispr Therapeutics AG annual total liabilities history from 2015 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Crispr Therapeutics AG total liabilities as of December 31, 2025: 343.4M, a 10.80% increase year-over-year.
- Crispr Therapeutics AG total liabilities for 2025 were 343.4M, a 10.80% increase from 2024.
- Crispr Therapeutics AG total liabilities for 2024 were 310.0M, a 10.62% decrease from 2023.
- Crispr Therapeutics AG total liabilities for 2023 were 346.8M, a 5.66% decrease from 2022.
- Crispr Therapeutics AG total liabilities for 2022 were 367.6M.
Total Liabilities
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Crispr Therapeutics AG Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $343 |
| 2024 | $310 |
| 2023 | $347 |
| 2022 | $368 |
| 2021 | $352 |
| 2020 | $164 |
| 2019 | $127 |
| 2018 | $97 |
| 2017 | $84 |
| 2016 | $112 |
| 2015 | $124 |
Crispr Therapeutics AG Total Liabilities — FAQ
Crispr Therapeutics AG (CRSP) total liabilities over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRSP's total liabilities history?
The chart and table above show Crispr Therapeutics AG's total liabilities by year and by quarter, including the growth rate.